NanoViricides, Inc. (NYSE American: NNVC) announced it will participate in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City. Anil R. Diwan, Ph.D., president and executive chairman, will hold one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. The event provides an opportunity for the company to discuss its progress and future plans, particularly regarding its lead drug candidate, NV-387.
NV-387 is a broad-spectrum antiviral drug designed to treat respiratory viral infections such as RSV, COVID-19, Long COVID, influenza, and others. It has also shown effectiveness in animal models for monkeypox, smallpox, and measles. The drug candidate recently completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is now focused on advancing NV-387 into Phase II human clinical trials.
The conference participation comes at a critical time for NanoViricides as it seeks to move its pipeline forward. The company also has another advanced drug candidate, NV-HHV-1, intended for the treatment of herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV shingles, and chickenpox. However, the company has not projected an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to reliance on external collaborators and consultants.
For investors and industry observers, the conference offers a chance to gain insights into NanoViricides' strategic direction and the potential impact of NV-387. The successful completion of Phase I trials with no adverse events is a significant milestone, positioning NV-387 as a promising candidate in the antiviral space. The company's broad-spectrum approach could address multiple viral threats, which is particularly relevant given the ongoing challenges posed by respiratory viruses and emerging pathogens.
More information about NanoViricides is available at www.nanoviricides.com. The latest news and updates relating to NNVC can be found in the company’s newsroom at https://ibn.fm/NNVC. For details on the press release, visit https://ibn.fm/YxQyd.
